David Linetsky Sells 6,106 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) insider David Linetsky sold 6,106 shares of the stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total transaction of $103,863.06. Following the completion of the transaction, the insider directly owned 231,723 shares of the company’s stock, valued at $3,941,608.23. The trade was a 2.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

David Linetsky also recently made the following trade(s):

• On Wednesday, December 17th, David Linetsky sold 94 shares of Phreesia stock. The stock was sold at an average price of $16.49, for a total transaction of $1,550.06.
• On Friday, October 17th, David Linetsky sold 2,059 shares of Phreesia stock. The shares were sold at an average price of $22.36, for a total transaction of $46,039.24.

Phreesia Trading Down 3.4%

NYSE:PHR opened at $16.55 on Wednesday. Phreesia, Inc. has a 12 month low of $15.41 and a 12 month high of $32.76. The firm has a fifty day simple moving average of $18.72 and a 200-day simple moving average of $23.53. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $998.04 million, a P/E ratio of -165.52 and a beta of 0.61.

Phreesia (NYSE:PHR) last released its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.11. The firm had revenue of $120.33 million for the quarter, compared to the consensus estimate of $119.98 million. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The firm’s revenue was up 12.7% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.25) EPS. On average, equities research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Latest reported quarter showed revenue and EPS upside (revenue $120.3M, EPS $0.10 vs. consensus ~($0.01)), which supports the company’s growth story and could cap downside after the sell‑off. MarketBeat: Phreesia earnings summary
• Neutral Sentiment: Royal Bank of Canada initiated coverage on PHR this week — initiations often boost visibility and trading volume but don’t always change consensus direction immediately. RBC initiates coverage on Phreesia
• Negative Sentiment: Citigroup cut its price target on PHR to $25 (from $29), reducing upside expectations from a widely followed sell‑side shop; such changes can pressure sentiment among investors tracking analyst targets. Citigroup cuts Phreesia price target to $25
• Negative Sentiment: Multiple senior insiders sold shares on Jan. 8 (CFO Balaji Gandhi, General Counsel Allison Hoffman, EVP/other officers including Amy Beth Vanduyn, Evan Roberts and David Linetsky). Collective Form 4 filings show routine but sizable sales around ~$17/share, which increases float and can be read as reduced near‑term insider conviction. Insider selling report

Hedge Funds Weigh In On Phreesia

Several large investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its holdings in Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock worth $617,000 after buying an additional 16,309 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Phreesia by 471.2% in the first quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock worth $4,090,000 after acquiring an additional 132,015 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock worth $1,599,000 after acquiring an additional 2,158 shares in the last quarter. NewEdge Advisors LLC grew its position in shares of Phreesia by 262.7% during the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after acquiring an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Phreesia by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock valued at $15,336,000 after purchasing an additional 2,402 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on PHR shares. Royal Bank Of Canada began coverage on Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 target price on the stock. Citigroup decreased their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, January 9th. Barclays cut their price objective on shares of Phreesia from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 16th. Needham & Company LLC reissued a “buy” rating and set a $35.00 target price on shares of Phreesia in a report on Monday, December 8th. Finally, Robert W. Baird lowered their price target on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday, December 10th. Seventeen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Phreesia has an average rating of “Moderate Buy” and an average target price of $30.06.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.